NEW YORK – Codexis announced Monday an agreement to license its EvoT4 DNA ligase enzyme to Roche.
The firm said it expects Roche to incorporate the enzyme in next-generation sequencing library preparation kits and other sequencing products.
Under the terms of the license, Roche gained worldwide rights to include EvoT4 DNA ligase in its nucleic acid sequencing products and workflows. Roche will pay Codexis royalties; other financial details were not disclosed.
"We are very excited to license our first product targeting this market to Roche Sequencing Solutions. This deal underscores our belief in genomic sequencing as an attractive commercial target for our company, and we look forward to future successful introductions of additional CodeEvolver-derived innovations in this and other Life Science applications," Codexis CEO and President John Nicols said in a statement.
Codexis, a Redwood City, California-based protein engineering company, developed the EvoT4 enzyme to improve the efficiency and speed of adapter ligation for low-input DNA samples.